GU Oncology Now (@guoncologynow) 's Twitter Profile Photo

A roundtable discussion led by Dr. Christopher Wallis (he/him/his) featuring Drs. Sia Daneshmand, M.D., Piyush Kumar Agarwal, and Sima Porten focused on treatment considerations for non-muscle invasive #bladdercancer, including recent data from #SUO2023. Watch the full video here: buff.ly/3v9GlWR

ArteraAI (@arteraai) 's Twitter Profile Photo

Did you catch the #ArteraAI team at #SUO2023? Dr. Eric Li presented on the abstract validating ArteraAI's #prognostic biopsy #MMAI model in patients undergoing radical prostatectomy - part of the Young Urologic Oncologists (YUO) Program. ➡️ Learn more at artera.ai

Did you catch the #ArteraAI team at #SUO2023?

Dr. Eric Li presented on the abstract validating ArteraAI's #prognostic biopsy #MMAI model in patients undergoing radical prostatectomy - part of the Young Urologic Oncologists (YUO) Program.

➡️ Learn more at artera.ai
Journal of the @NCCN (@jnccn) 's Twitter Profile Photo

#SUO2023: Is Radioligand Therapy Safe for Patients With #ProstateCancer and Baseline Cytopenia? jnccn360.org/prostate/news/… #JNCCN360 #PCSM

#SUO2023: Is Radioligand Therapy Safe for Patients With #ProstateCancer and Baseline Cytopenia? jnccn360.org/prostate/news/… #JNCCN360 #PCSM
GU Oncology Now (@guoncologynow) 's Twitter Profile Photo

A roundtable discussion led by Dr. Christopher Wallis (he/him/his) featuring Drs. Sia Daneshmand, M.D., Piyush Kumar Agarwal, and Sima Porten focused on patient selection and new therapies for non-muscle invasive #bladdercancer, as well as recent data from #SUO2023. Watch here: buff.ly/3GE2BdG

Sarah P. Psutka MD MS (@spsutkamd) 's Twitter Profile Photo

It took a while because we got official photos this year... #WUO #SUO2023. This is what a genuine commitment to inclusivity *will* cultivate! #WeMentorSponsorAlly #WidenThePath Society of Urologic Oncology

It took a while because we got official photos this year... #WUO #SUO2023. This is what a genuine commitment to inclusivity *will* cultivate! #WeMentorSponsorAlly #WidenThePath <a href="/UroOnc/">Society of Urologic Oncology</a>
GU Oncology Now (@guoncologynow) 's Twitter Profile Photo

New results of the EMBARK trial's secondary objective concerning the change from baseline patient-reported outcomes for pain and HRQOL were presented at #SUO2023 by Stephen Freedland, MD. Learn more: buff.ly/3uAUegd #SUO23

New results of the EMBARK trial's secondary objective concerning the change from baseline patient-reported outcomes for pain and HRQOL were presented at #SUO2023 by <a href="/SFreedlandMD/">Stephen Freedland, MD</a>. Learn more: buff.ly/3uAUegd
#SUO23
UrologyMSK (@urologymsk) 's Twitter Profile Photo

Wonderful meeting so many interested applicants at #suo2023! Our Society of Urologic Oncology interviews will be Friday April 12th with an optional reception Thursday evening. Applications open until March! YUO

CG Oncology, Inc. (@cgoncology) 's Twitter Profile Photo

Our Phase 3 BOND-003 data presented at #SUO2023 shows a 75.7% response w/cretostimogene grenadenorepvec in #BCG-unresponsive #NMIBC patients. Thanks, Urology Times & UroToday.com, for sharing this "promising new #monotherapy." 👉 bit.ly/47EczYh + bit.ly/3sTnluZ

Our Phase 3 BOND-003 data presented at #SUO2023 shows a 75.7% response w/cretostimogene grenadenorepvec in #BCG-unresponsive #NMIBC  patients. Thanks, <a href="/UrologyTimes/">Urology Times</a> &amp; <a href="/UroToday/">UroToday.com</a>, for sharing this "promising new #monotherapy."

👉 bit.ly/47EczYh + bit.ly/3sTnluZ
GU Oncology Now (@guoncologynow) 's Twitter Profile Photo

Pretreatment carcinoma in situ and pretreatment positive urinary cytology may carry potential predictive benefits for patients with non-muscle invasive #bladdercancer. Learn more about this new study presented at #SUO2023: buff.ly/46Ssf9v #SUO23

Pretreatment carcinoma in situ and pretreatment positive urinary cytology may carry potential predictive benefits for patients with non-muscle invasive #bladdercancer. Learn more about this new study presented at #SUO2023: buff.ly/46Ssf9v
#SUO23
Ippokratis Korantzis, Medical Oncologist, MD, PhD (@newsincancer) 's Twitter Profile Photo

Targeted therapy produces Lasting Responses in BCG-Unresponsive, High-Risk NMIBC. #bladdercancer, #SUO2023 suo-abstracts.secure-platform.com/a/gallery/roun…

Targeted therapy produces Lasting Responses in BCG-Unresponsive, High-Risk NMIBC.
#bladdercancer, #SUO2023 
suo-abstracts.secure-platform.com/a/gallery/roun…
Danly Omil-Lima, MD (@domillima) 's Twitter Profile Photo

#SUO2023 was a blast. Exciting programming and great to catch up with friends from fellowship interview trail. Amazing representation from Fox Chase Cancer Center Department of Urology. And such a trip to talk to prospective applicants after being in their shoes not too long ago. Feeling re-energized! Society of Urologic Oncology

#SUO2023 was a blast. Exciting programming and great to catch up with friends from fellowship interview trail. Amazing representation from <a href="/FCUroOnc/">Fox Chase Cancer Center Department of Urology</a>. And such a trip to talk to prospective applicants after being in their shoes not too long ago. Feeling re-energized! <a href="/UroOnc/">Society of Urologic Oncology</a>
GU Oncology Now (@guoncologynow) 's Twitter Profile Photo

At #SUO2023, Tian Zhang, MD, MHS presented the results of a post hoc exploratory analysis on DFS in patient subgroups from KEYNOTE-564 based on the UCLA Integrated Staging System risk groups and disease stage. Learn more: buff.ly/49XxFCI #SUO23

At #SUO2023, <a href="/TiansterZhang/">Tian Zhang, MD, MHS</a> presented the results of a post hoc exploratory analysis on DFS in patient subgroups from KEYNOTE-564 based on the UCLA Integrated Staging System risk groups and disease stage. Learn more: buff.ly/49XxFCI
#SUO23
Bogdana Schmidt MD, MPH (@bogdanaschmidt) 's Twitter Profile Photo

Wrapping up awesome #SUO2023 and putting in a plug for friends to come to #MOGULS24 in beautiful Park City February 8-10, 2024 with awesome ⛷️ and more cancer talks with Sia Daneshmand, M.D. Benjamin L Maughan Skyler Johnson, MD Alejandro Sanchez, MD na.eventscloud.com/ehome/moguls/a… University of Utah Urology Intermountain Health

Chad Ritch (@chadritchmd) 's Twitter Profile Photo

Effective mutliD cancer care is challenging….strong teamwork is key! It makes a big difference to have great colleagues to work with. Thanks to Alan Dal Pra, MD Suzanne Cole, MD Sumanta K. Pal, MD, FASCO Ulka Vaishampayan for sharing #radonc #medonc knowledge with us surgeons! #kidneycancer #SUO2023

Effective mutliD cancer care is challenging….strong teamwork is key! It makes a big difference to have great colleagues to work with. Thanks to <a href="/a_dalpra/">Alan Dal Pra, MD</a> <a href="/SuzanneColeMD/">Suzanne Cole, MD</a> <a href="/montypal/">Sumanta K. Pal, MD, FASCO</a> <a href="/DrVaishampayan/">Ulka Vaishampayan</a> for sharing #radonc #medonc knowledge with us surgeons! #kidneycancer #SUO2023
Chad Ritch (@chadritchmd) 's Twitter Profile Photo

Superb #SUO2023 panel on how to manage recurrences in #kidneycancer. Really great perspective from this outstanding panel Suzanne Cole, MD Alan Dal Pra, MD Harras Zaid Ulka Vaishampayan, Vitaly Margulis, Andrew James, Meredith Metcalf

Superb #SUO2023 panel on how to manage recurrences in #kidneycancer. Really great perspective from this outstanding panel <a href="/SuzanneColeMD/">Suzanne Cole, MD</a> <a href="/a_dalpra/">Alan Dal Pra, MD</a> <a href="/hbzaid/">Harras Zaid</a> Ulka Vaishampayan, Vitaly Margulis, Andrew James, Meredith Metcalf